About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Companion Diagnostics for Oncology Market Size, Share and Forecast to 2031
Companion Diagnostics for Oncology Market

Companion Diagnostics for Oncology Market Size, Share & Trends Analysis Report By Products and Services (Assays, Kits, and Reagents, Software and Services), By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS)), By Indication (Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma, Others), By End-User (Pharmaceutical and Biopharmaceutical Companies, Laboratories, Contract Research Organizations, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRHI3616DR
Last Updated : March 15, 2023
Author : Straits Research
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Companion Diagnostics for Oncology Market Introduction
    2. By Products and Services
      1. Introduction
        1. Products and Services By Value
      2. Assays, Kits, and Reagents
        1. By Value
      3. Software and Services
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR)
        1. By Value
      3. Next-Generation Sequencing (NGS)
        1. By Value
    4. By Indication
      1. Introduction
        1. Indication By Value
      2. Breast Cancer
        1. By Value
      3. Lung Cancer
        1. By Value
      4. Colorectal Cancer
        1. By Value
      5. Gastric Cancer
        1. By Value
      6. Melanoma
        1. By Value
      7. Others
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biopharmaceutical Companies
        1. By Value
      3. Laboratories
        1. By Value
      4. Contract Research Organizations
        1. By Value
      5. Others
        1. By Value
    1. Introduction
    2. By Products and Services
      1. Introduction
        1. Products and Services By Value
      2. Assays, Kits, and Reagents
        1. By Value
      3. Software and Services
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR)
        1. By Value
      3. Next-Generation Sequencing (NGS)
        1. By Value
    4. By Indication
      1. Introduction
        1. Indication By Value
      2. Breast Cancer
        1. By Value
      3. Lung Cancer
        1. By Value
      4. Colorectal Cancer
        1. By Value
      5. Gastric Cancer
        1. By Value
      6. Melanoma
        1. By Value
      7. Others
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biopharmaceutical Companies
        1. By Value
      3. Laboratories
        1. By Value
      4. Contract Research Organizations
        1. By Value
      5. Others
        1. By Value
    6. U.S.
      1. By Products and Services
        1. Introduction
          1. Products and Services By Value
        2. Assays, Kits, and Reagents
          1. By Value
        3. Software and Services
          1. By Value
      2. By Technology
        1. Introduction
          1. Technology By Value
        2. Polymerase Chain Reaction (PCR)
          1. By Value
        3. Next-Generation Sequencing (NGS)
          1. By Value
      3. By Indication
        1. Introduction
          1. Indication By Value
        2. Breast Cancer
          1. By Value
        3. Lung Cancer
          1. By Value
        4. Colorectal Cancer
          1. By Value
        5. Gastric Cancer
          1. By Value
        6. Melanoma
          1. By Value
        7. Others
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical and Biopharmaceutical Companies
          1. By Value
        3. Laboratories
          1. By Value
        4. Contract Research Organizations
          1. By Value
        5. Others
          1. By Value
    7. Canada
    1. Introduction
    2. By Products and Services
      1. Introduction
        1. Products and Services By Value
      2. Assays, Kits, and Reagents
        1. By Value
      3. Software and Services
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR)
        1. By Value
      3. Next-Generation Sequencing (NGS)
        1. By Value
    4. By Indication
      1. Introduction
        1. Indication By Value
      2. Breast Cancer
        1. By Value
      3. Lung Cancer
        1. By Value
      4. Colorectal Cancer
        1. By Value
      5. Gastric Cancer
        1. By Value
      6. Melanoma
        1. By Value
      7. Others
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biopharmaceutical Companies
        1. By Value
      3. Laboratories
        1. By Value
      4. Contract Research Organizations
        1. By Value
      5. Others
        1. By Value
    6. U.K.
      1. By Products and Services
        1. Introduction
          1. Products and Services By Value
        2. Assays, Kits, and Reagents
          1. By Value
        3. Software and Services
          1. By Value
      2. By Technology
        1. Introduction
          1. Technology By Value
        2. Polymerase Chain Reaction (PCR)
          1. By Value
        3. Next-Generation Sequencing (NGS)
          1. By Value
      3. By Indication
        1. Introduction
          1. Indication By Value
        2. Breast Cancer
          1. By Value
        3. Lung Cancer
          1. By Value
        4. Colorectal Cancer
          1. By Value
        5. Gastric Cancer
          1. By Value
        6. Melanoma
          1. By Value
        7. Others
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical and Biopharmaceutical Companies
          1. By Value
        3. Laboratories
          1. By Value
        4. Contract Research Organizations
          1. By Value
        5. Others
          1. By Value
    7. Germany
    8. France
    9. Spain
    10. Italy
    11. Russia
    12. Nordic
    13. Benelux
    14. Rest of Europe
    1. Introduction
    2. By Products and Services
      1. Introduction
        1. Products and Services By Value
      2. Assays, Kits, and Reagents
        1. By Value
      3. Software and Services
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR)
        1. By Value
      3. Next-Generation Sequencing (NGS)
        1. By Value
    4. By Indication
      1. Introduction
        1. Indication By Value
      2. Breast Cancer
        1. By Value
      3. Lung Cancer
        1. By Value
      4. Colorectal Cancer
        1. By Value
      5. Gastric Cancer
        1. By Value
      6. Melanoma
        1. By Value
      7. Others
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biopharmaceutical Companies
        1. By Value
      3. Laboratories
        1. By Value
      4. Contract Research Organizations
        1. By Value
      5. Others
        1. By Value
    6. China
      1. By Products and Services
        1. Introduction
          1. Products and Services By Value
        2. Assays, Kits, and Reagents
          1. By Value
        3. Software and Services
          1. By Value
      2. By Technology
        1. Introduction
          1. Technology By Value
        2. Polymerase Chain Reaction (PCR)
          1. By Value
        3. Next-Generation Sequencing (NGS)
          1. By Value
      3. By Indication
        1. Introduction
          1. Indication By Value
        2. Breast Cancer
          1. By Value
        3. Lung Cancer
          1. By Value
        4. Colorectal Cancer
          1. By Value
        5. Gastric Cancer
          1. By Value
        6. Melanoma
          1. By Value
        7. Others
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical and Biopharmaceutical Companies
          1. By Value
        3. Laboratories
          1. By Value
        4. Contract Research Organizations
          1. By Value
        5. Others
          1. By Value
    7. Korea
    8. Japan
    9. India
    10. Australia
    11. Taiwan
    12. South East Asia
    13. Rest of Asia-Pacific
    1. Introduction
    2. By Products and Services
      1. Introduction
        1. Products and Services By Value
      2. Assays, Kits, and Reagents
        1. By Value
      3. Software and Services
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR)
        1. By Value
      3. Next-Generation Sequencing (NGS)
        1. By Value
    4. By Indication
      1. Introduction
        1. Indication By Value
      2. Breast Cancer
        1. By Value
      3. Lung Cancer
        1. By Value
      4. Colorectal Cancer
        1. By Value
      5. Gastric Cancer
        1. By Value
      6. Melanoma
        1. By Value
      7. Others
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biopharmaceutical Companies
        1. By Value
      3. Laboratories
        1. By Value
      4. Contract Research Organizations
        1. By Value
      5. Others
        1. By Value
    6. UAE
      1. By Products and Services
        1. Introduction
          1. Products and Services By Value
        2. Assays, Kits, and Reagents
          1. By Value
        3. Software and Services
          1. By Value
      2. By Technology
        1. Introduction
          1. Technology By Value
        2. Polymerase Chain Reaction (PCR)
          1. By Value
        3. Next-Generation Sequencing (NGS)
          1. By Value
      3. By Indication
        1. Introduction
          1. Indication By Value
        2. Breast Cancer
          1. By Value
        3. Lung Cancer
          1. By Value
        4. Colorectal Cancer
          1. By Value
        5. Gastric Cancer
          1. By Value
        6. Melanoma
          1. By Value
        7. Others
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical and Biopharmaceutical Companies
          1. By Value
        3. Laboratories
          1. By Value
        4. Contract Research Organizations
          1. By Value
        5. Others
          1. By Value
    7. Turkey
    8. Saudi Arabia
    9. South Africa
    10. Egypt
    11. Nigeria
    12. Rest of MEA
    1. Introduction
    2. By Products and Services
      1. Introduction
        1. Products and Services By Value
      2. Assays, Kits, and Reagents
        1. By Value
      3. Software and Services
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR)
        1. By Value
      3. Next-Generation Sequencing (NGS)
        1. By Value
    4. By Indication
      1. Introduction
        1. Indication By Value
      2. Breast Cancer
        1. By Value
      3. Lung Cancer
        1. By Value
      4. Colorectal Cancer
        1. By Value
      5. Gastric Cancer
        1. By Value
      6. Melanoma
        1. By Value
      7. Others
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biopharmaceutical Companies
        1. By Value
      3. Laboratories
        1. By Value
      4. Contract Research Organizations
        1. By Value
      5. Others
        1. By Value
    6. Brazil
      1. By Products and Services
        1. Introduction
          1. Products and Services By Value
        2. Assays, Kits, and Reagents
          1. By Value
        3. Software and Services
          1. By Value
      2. By Technology
        1. Introduction
          1. Technology By Value
        2. Polymerase Chain Reaction (PCR)
          1. By Value
        3. Next-Generation Sequencing (NGS)
          1. By Value
      3. By Indication
        1. Introduction
          1. Indication By Value
        2. Breast Cancer
          1. By Value
        3. Lung Cancer
          1. By Value
        4. Colorectal Cancer
          1. By Value
        5. Gastric Cancer
          1. By Value
        6. Melanoma
          1. By Value
        7. Others
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical and Biopharmaceutical Companies
          1. By Value
        3. Laboratories
          1. By Value
        4. Contract Research Organizations
          1. By Value
        5. Others
          1. By Value
    7. Mexico
    8. Argentina
    9. Chile
    10. Colombia
    11. Rest of LATAM
    1. Companion Diagnostics for Oncology Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Qiagen N.V.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. F. Hoffmann La Roche Ltd
    3. Agilent Technologies
    4. Thermo Fisher Scientific
    5. Abbott
    6. Amoy diagnostics
    7. BioMérieux SA
    8. Archerdx
    9. Illumina, Inc.
    10. Foundation Medicine, Inc.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The global companion diagnostics market size was valued at USD 5.37 billion in 2023. It is estimated to reach USD 15.87 billion by 2032, growing at a CAGR of 12.8% during the forecast period (2024–2032). The growing prevalence of chronic diseas
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.